2seventy bio Inc. (TSVT) News
Filter TSVT News Items
TSVT News Results
|Loading, please wait...|
TSVT News Highlights
- For TSVT, its 30 day story count is now at 4.
- Over the past 11 days, the trend for TSVT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BIO, AL and ABSI are the most mentioned tickers in articles about TSVT.
Latest TSVT News From Around the Web
Below are the latest news stories about 2seventy bio Inc that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
CAMBRIDGE, Mass., February 14, 2022--2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the role of chief medical officer (CMO). Also announced today, Susan Abu-Absi, Ph.D. has been appointed chief technology & manufacturing officer at 2seventy bio.
CAMBRIDGE, Mass., February 14, 2022--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences:
Every investor in 2seventy bio, Inc. ( NASDAQ:TSVT ) should be aware of the most powerful shareholder groups. Generally...
Richmond, VA, based Investment company Virginia Retirement Systems Et Al (Current Portfolio) buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings Inc, 2seventy bio Inc, Loyalty Ventures Inc, sells American Water Works Co Inc, Johnson & Johnson, Activision Blizzard Inc, Intuit Inc, Dollar General Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Virginia Retirement Systems Et Al.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil
CAMBRIDGE, Mass., January 11, 2022--2seventy bio, Inc. (Nasdaq: TSVT), an emerging immuno-oncology cell therapy company, today provided an update on the company’s outlook for 2022.
2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach
CAMBRIDGE, Mass., January 06, 2022--2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology fo
CAMBRIDGE, Mass., December 13, 2021--2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and new analyses from the pivotal KarMMa study of ABECMA® (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma, both in partnership with Bristol Myers Squibb (BMS). The company also presented preclinical data on the investigational CD33-targeted autologou
2seventy bio Inc (NASDAQ:TSVT) Stock analysts at Wedbush increased their FY2021 earnings per share (EPS) estimates for 2seventy bio in a note issued to investors on Wednesday, December 1st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($15.17) per share for the year, up from their prior forecast of 
No summary available.